NICE TA684 - adjuvant treatment of completely resected melanoma with lymph node involvement or metastatic disease. Replaces NICE TA558. (Decision date - April 2021)
NICE TA707 - Nivolumab for previously treated
unresectable advanced or recurrent oesophageal cancer (Decision date - July 2021)
NICE TA713 - for non-squamous non-small-cell lung cancer (NSCLC) in adults after
chemotherapy (Decision date - August 2021)
NICE TA716 - Nivolumab plus ipilimumab for treating metastatic colorectal cancer with
high microsatellite instability or mismatch repair deficiency (Decision date - August 2021)
NICE TA724- Nivolumab with ipilimumab and chemotherapy for untreated
metastatic nonsmall-cell lung cancer (Decision date - Oct 2021)
NICE TA736 - Nivolumab for treating recurrent or metastatic squamous cell carcinoma of the head and neck after platinum-based chemotherapy. (Decision date - Nov 2021)
NICE TA746 - Nivolumab for adjuvant treatment of resected oesophageal or gastro-oesophageal junction cancer. (Decision date - December 2021)
NICE TA780 - Nivolumab with ipilimumab for untreated advanced renal cell
carcinoma (Decision date - April 2022)
NICE TA817 - Nivolumab for adjuvant treatment of
invasive urothelial cancer at high risk of recurrence (Decision date - September 2022)
NICE TA818 - Nivolumab with ipilimumab for untreated
unresectable malignant pleural mesothelioma (Decision date - September 2022)
SSC2431 - nivolumab with fluoropyrimidine- and platinum-based
chemotherapy for untreated unresectable advanced recurrent or metastatic
oesophageal squamous cell carcinoma. NHSE commissioned. (Decision date - November 2022)
NICE TA857 - Nivolumab with platinum- and fluoropyrimidine-based chemotherapy for untreated HER2-negative advanced gastric, gastro-oesophageal junction or oesophageal adenocarcinoma. NHSE commissioned. (Decision date - February 2023)
NICE TA865 - Nivolumab with fluoropyrimidine- and platinum-based chemotherapy for untreated unresectable advanced, recurrent, or metastatic oesophageal squamous cell carcinoma. (Decision date - March 2023)
NICE TA876 - Nivolumab with chemotherapy for neoadjuvant treatment of resectable non-small-cell lung cancer. (Decision date - April 2023)
DO NOT PRESCRIBE (DNP):
NICE TA530:For treating locally advanced unresectable or metastatic urothelial cancer after platinum-containing chemotherapy (Decision date - August 2018)
NICE TA980: for adjuvant treatment of completely resected melanoma at high risk of recurrence in people 12 years and over (terminated appraisal) - (Decision date July 2024)
Do Not Prescribe (DNP) Drug Classifications
6: Have NICE guidance that recommends they should not be used
Red Drug Classifications
1: Requiring specialist assessment to enable patient selection, initiation and ongoing treating
2: Requiring long term on-going monitoring of efficacy by a specialist and not suitable for shared care
3: Requiring long term on-going monitoring of toxicity by a specialist (either because of difficulty in recognising side effects or high cost of investigations to identify toxicity)
8. NHS England commissioned – to be used in line with NHSE commissioning intentions
